ADIM
MRVI icon

Alpha DNA Investment Management’s Maravai LifeSciences MRVI Stock Holding History

Alpha DNA Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,037
Closed -$408K – 231
2024
Q2 		$408K Buy
+57,037
New +$492K 0.16% 160

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Alpha DNA Investment Management's MRVI Position: Q3 2024 in Review

Alpha DNA Investment Management sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 57,037 shares — an estimated $408K sold.

Alpha DNA Investment Management first reported a position in MRVI in Q2 2024 and held it in 1 quarter. The position peaked at $408K in Q2 2024. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

  • Alpha DNA Investment Management reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 57,037 Maravai LifeSciences shares in Q3 2024, an estimated $408K.
  • Alpha DNA Investment Management first reported a position in Maravai LifeSciences in Q2 2024 and held it in 1 quarter.
  • Alpha DNA Investment Management's Maravai LifeSciences position peaked at $408K in Q2 2024.
  • 217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Alpha DNA Investment Management's 13F filing for Q3 2024, filed 12 Nov 2024.